Return on Sales by Net Profit: exicuretx.com (XCUR)

exicuretx.com (XCUR) - corporate logo

Exicure, Inc. (XCUR) develops scalable gene therapy methods where low synthesis costs expand the product pipeline. The net margin as a percentage of revenue illustrates current profitability, while the 0.00 mark indicates the level of competitiveness. Business stability relies on strategic grants regardless of GDP; however, significant risks of delisting and strategic pivots necessitate caution.

Exicure Inc. (XCUR) - Return on Sales by Net Profit from 07/04/2022 to 11/19/2026

exicuretx.com (XCUR) - metric breakdowns and financial figures

- share price and consensus valuation forecast:
- company stock exchange capitalization indicators:
Summary company analysis:Exicure, Inc.
Manufactured product of Exicure, Inc.

Exicure, Inc. operates in the high-risk biotechnology sector. An analysis of the net profit margin allows for an assessment of the efficiency with which sales are converted into net income after all expenses are deducted. This metric measures the business's ability to generate real cash flow amidst a shortage of working capital. For a company in an asset restructuring phase, a negative trend in this indicator signals a critical increase in operating expenses. A stable recovery of this metric will serve as a key signal for the reduction of liquidity risks.

Key competitors

TEM: Net Sales Margin|Net Profitability Margin Qiagen QGEN|IONS (Isis Pharmaceuticals) - Net Sales Margin|Repligen Inc. - Net Profit Margin|Net Sales Margin RNA|CRSP - Net Margin|GeneDx - Return on Sales by Net Profit|Net Profit Rate RARE|Beam Tx - Net Sales Margin|SRPT - Net Sales Margin|TWST (Twist Bio) - Return on Sales by Net Profit|Net Return on Sales TXG|Return on Sales by Net Profit NTLA|Stoke Therapeutics Inc (STOK) - Company Sales Margin|Net Sales Margin BLFS|Net Margin WVE (Wave Life Sciences Corp)|Net Margin Maze Therapeutics MAZE|Net Profit Rate SION|PRME - Net Margin|Company Sales Margin Taysha TSHA|QURE: Net Sales Margin|Return on Sales by Net Profit MeiraGTx PLC|RGNX (REGENXBIO Inc) - Net Sales Margin|solidbio.com (SLDB) - Company Sales Margin|Net Margin Ocugen Corp (OCGN)|Pacific Biosciences of California, Inc. - Net Return on Sales|Benitec Biopharma - Return on Sales by Net Profit|DSGN: Net Return on Sales|RCKT: Return on Sales by Net Profit|FDMT - Net Sales Margin|LXEO: Net Sales Margin|Korro Bio Inc. - Net Profit Rate|EDIT (editasmedicine.com) - Net Sales Margin|Net Margin SLN|Net Margin ProQR Therapeutics NV (PRQR)|Codexis - Net Return on Sales|Net Margin Sangamo SGMO|NAUT: Net Return on Sales|MGX: Return on Sales by Net Profit|Net Margin Precision BioSciences|GBIO (generationbio.com) - Return on Sales by Net Profit|Net Margin boundlessbio.com (BOLD)|Net Margin Imunon|Phio Pharmaceuticals - Net Profit Margin|Net Margin Mustang Bio, Inc. (MBIO)|Company Sales Margin TransCode Therapeutics, Inc.|Net Margin Bionano Genomics BNGO|Net Profit Rate APDN|BLUE - Net Margin|Net Profit Margin IPA|Omega Therapeutics, Inc. (OMGA) - Net Margin|Singular Genomics Corp (OMIC) - Net Sales Margin|RGLS (Regulus Therapeutics, Inc.) - Net Sales Margin|SYRS: Net Profit Rate|Return on Sales by Net Profit TBIO (Telesis Bio Inc.)|Net Sales Margin TRACON Pharmaceuticals Inc. (TCON)|Net Margin Unity Bio UBX